Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AVITA Medical (RCEL) Cash from Operations (2019 - 2025)

Historic Cash from Operations for AVITA Medical (RCEL) over the last 7 years, with Q4 2025 value amounting to -$5.4 million.

  • AVITA Medical's Cash from Operations rose 3270.63% to -$5.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$31.2 million, marking a year-over-year increase of 3625.74%. This contributed to the annual value of -$31.2 million for FY2025, which is 3625.74% up from last year.
  • As of Q4 2025, AVITA Medical's Cash from Operations stood at -$5.4 million, which was up 3270.63% from -$5.2 million recorded in Q3 2025.
  • In the past 5 years, AVITA Medical's Cash from Operations registered a high of $252000.0 during Q2 2022, and its lowest value of -$20.9 million during Q1 2024.
  • Moreover, its 5-year median value for Cash from Operations was -$9.0 million (2023), whereas its average is -$8.5 million.
  • Its Cash from Operations has fluctuated over the past 5 years, first soared by 10201.02% in 2022, then plummeted by 371150.79% in 2023.
  • Over the past 5 years, AVITA Medical's Cash from Operations (Quarter) stood at -$572000.0 in 2021, then tumbled by 500.7% to -$3.4 million in 2022, then crashed by 216.15% to -$10.9 million in 2023, then rose by 25.61% to -$8.1 million in 2024, then skyrocketed by 32.71% to -$5.4 million in 2025.
  • Its Cash from Operations stands at -$5.4 million for Q4 2025, versus -$5.2 million for Q3 2025 and -$10.2 million for Q2 2025.